Central Nervous System Neoplasm Clinical Trial
Official title:
Cerebrospinal Fluid Biomarkers for Brain Tumors
This study examines cerebrospinal biomarkers in patients with brain tumors. A biomarker is a measurable indicator of the severity or presence of your disease state. Collecting and storing samples of cerebrospinal fluid from patients with brain tumors to study in the laboratory may help doctors develop new strategies to better diagnose, monitor, and treat brain tumors.
| Status | Recruiting |
| Enrollment | 300 |
| Est. completion date | December 31, 2025 |
| Est. primary completion date | December 31, 2024 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Any evidence of neoplasm involving the central nervous system (CNS) or its adjacent structures in contact with CSF. Such lesions may include but are not limited to intra-axial or extra-axial lesions, which could be benign, malignant or as yet undefined, involving the brain, spine, meninges, nerves, or vasculature or supporting structures - Subjects must be 18 years of age or older Exclusion Criteria: - Patients who are under 18 years of age or are a member of a vulnerable population will be excluded from this study - Pregnant women or women who may be pregnant are specifically excluded from study participation - Exception will be granted for patients with diminished capacity to consent if a legally authorized representative is available - Patients without clinical or radiographic evidence of a potentially neoplastic CNS lesion will be excluded - Patients with an inability or unwillingness of individual or legal guardian/representative to give written informed consent will be excluded - Any patient for whom a clinical contraindication exists to the intended route of CSF access will be excluded. For example, a patient with a large posterior fossa mass lesion at risk of herniation, or a patient with coagulopathy, or other contraindication to lumbar puncture would not be eligible to participate via use of lumbar puncture for CSF access |
| Country | Name | City | State |
|---|---|---|---|
| United States | Mayo Clinic in Rochester | Rochester | Minnesota |
| Lead Sponsor | Collaborator |
|---|---|
| Mayo Clinic | National Cancer Institute (NCI), National Institute of Neurological Disorders and Stroke (NINDS) |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Collection cerebrospinal fluid (CSF) samples that can provide a resource to the research community for biomarker discovery | Up to study completion | ||
| Secondary | Feasibility of serial cerebrospinal fluid (CSF) sampling | Up to study completion |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04539574 -
An Investigational Scan (7T MRI) for the Imaging of Central Nervous System Tumors
|
N/A | |
| Completed |
NCT01474174 -
Trivalent Influenza Vaccine in Preventing Flu in Patients With Central Nervous System Tumors
|
||
| Completed |
NCT03071913 -
Blood Brain Barrier Differences in Patients With Brain Tumors Undergoing Surgery
|
||
| Recruiting |
NCT03270059 -
Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System
|
Phase 2 | |
| Active, not recruiting |
NCT03834961 -
Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia
|
Phase 2 | |
| Recruiting |
NCT02402244 -
Project: Every Child for Younger Patients With Cancer
|
||
| Completed |
NCT01217437 -
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
|
Phase 2 | |
| Completed |
NCT01941758 -
High-Dose Trivalent Influenza Vaccine in Inducing Immune Response Patients With Central Nervous System Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT02867592 -
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
|
Phase 2 | |
| Recruiting |
NCT00898755 -
Collecting and Storing Tissue From Young Patients With Cancer
|
||
| Completed |
NCT00100802 -
Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas
|
Phase 2 | |
| Completed |
NCT03012620 -
Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types
|
Phase 2 | |
| Completed |
NCT01538095 -
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
|
Phase 1 | |
| Withdrawn |
NCT05169151 -
Mobility and Physical Activity in Adolescent and Young Adult Cancer Patients or Survivors at Risk for Cardiovascular Morbidity and Frailty, The MOBILE AYA Study
|
||
| Recruiting |
NCT04988009 -
Patient Perceptions Around Quality of Care Through Telemedicine in Neuro-Oncology
|